Humane Genomics GTM brain

Humane Genomics develops investigational engineered oncolytic viruses intended to treat cancer, including pediatric liver cancer.

category

Oncolytic virus therapeutics

market profile

  • text: Cancer virotherapy developers must demonstrate tumor selectivity, clinical safety and effective manufacturing before commercialization.
  • text: The company has announced a manufacturing partnership for its lead candidate and presents research on pediatric liver cancer.

personas

  • title: Oncology pharma business development executive
    pains:
    • Needs differentiated cancer assets supported by reproducible translational data
    • Must evaluate clinical and manufacturing risks before licensing
  • title: Pediatric oncology clinical investigator
    pains:
    • Children with rare liver cancer need more treatment options
    • Needs evidence of tumor selectivity and safety before trials
  • title: Cancer research foundation program director
    pains:
    • Limited resources must support credible research for underserved cancers
    • Wants measurable milestones toward clinical translation

icp

  • text: Oncology-focused pharmaceutical partners with capacity to develop or license early-stage viral therapeutics; a prospective partner segment.
  • text: Pediatric cancer centers and translational research institutions with liver cancer expertise and clinical trial infrastructure.

message pillars

  • text: Design viral therapies to find cancer cells selectively.
  • text: Pursue selective infection and replication as complementary controls.
  • text: Advance a lead candidate toward manufacturing.

objections

  • objection: Has safety or efficacy been established in humans?
    response: The therapy is investigational; request the preclinical evidence and regulatory plan instead of assuming clinical results.
  • objection: Can a virus be manufactured consistently at clinical grade?
    response: The company announced a cGMP manufacturing partnership; partners should review process validation and supply milestones.

competitors

  • name: Replimune
    why: Develops oncolytic viral immunotherapies for cancer.
  • name: Candel Therapeutics
    why: Develops oncolytic viral immunotherapies in oncology.
  • name: Amgen
    why: Operates in the oncolytic virus cancer treatment landscape.

influencers

  • name: Chad Moles
    url: https://www.linkedin.com/in/chadmoles
    why: Co-founder and CSO shares research on engineered viral therapeutics.
  • name: Peter Weijmarshausen
    url: https://humanegenomics.com/news/introduction-peter-weijmarshausen/
    why: Founder explains the company's origins and cancer therapy vision.

keywords

  • oncolytic virus cancer therapy
  • pediatric liver cancer research
  • synthetic virology oncology
  • tumor selective viral therapy
  • oncolytic virus clinical manufacturing

voice

  • scientific
  • ambitious
  • precision-focused

signals

  • text: An oncology pharma company seeks external oncolytic virus assets or early-stage research collaborations.
  • text: A pediatric cancer center expands liver tumor research or early-phase clinical trial capacity.

pricing

model: unknown

motion

unknown

channels

  • scientific conferences
  • research publications
  • LinkedIn
  • biopharma partnerships

confidence

medium

Founders

  • name: Peter Weijmarshausen
    title: Founder
    role: Founder
    bio: Building a highly efficient platform to make artificial viruses as cancer therapeutics. Serial entrepreneur. Founder and former CEO of Shapeways. Have built and led software and product teams for 3 companies. Love to code, grow plants, brew beer, cook Asian food, and more. BSc Applied Physics.
  • name: Chad Moles
    title: Founder
    role: Founder
    bio: Building a platform to engineer viruses as precision cancer therapies. Previous: Biotech, Columbia & Public Health, Tulane. Interested in sailing and pickleball.

Back to YC companies